Clinical Trial Update: Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicates termination of a Phase 1/2 study evaluating an RNActive-derived vaccine for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• RNActive-derived Prostate Cancer Vaccine

Snippet

Sponsor: CureVac | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED